Research suggests that certain genetic mutations may be associated with survival rates after immunotherapy for ovarian cancer. Some studies have identified specific mutations, such as those in the PPP2R1A gene, as potential predictors of improved survival. However, the relevance of these findings to other types of cancer, such as melanoma, lung adenocarcinoma, and cervical squamous cell carcinoma, is also being explored, with various genetic markers and models being investigated to predict prognosis and response to immunotherapy.